Natera, Inc. (NASDAQ:NTRA) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 24.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,534 shares of the medical research company’s stock after selling 1,144 shares during the period. Snowden Capital Advisors LLC’s holdings in Natera were worth $559,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. LRI Investments LLC acquired a new stake in Natera in the 4th quarter worth about $29,000. Blue Trust Inc. boosted its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. boosted its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after buying an additional 332 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $154.53 on Wednesday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a 50 day simple moving average of $149.13 and a 200-day simple moving average of $157.15. The company has a market cap of $21.10 billion, a PE ratio of -87.80 and a beta of 1.79. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $501.83 million for the quarter, compared to analysts’ expectations of $446.68 million. During the same quarter in the previous year, the company earned ($0.56) earnings per share. The firm’s quarterly revenue was up 36.5% compared to the same quarter last year. On average, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 6,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the transaction, the insider now owns 143,768 shares of the company’s stock, valued at approximately $20,600,516.72. This represents a 4.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,562 shares of the business’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $138.41, for a total transaction of $354,606.42. Following the sale, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,436 shares of company stock valued at $22,019,079 over the last quarter. Corporate insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Saturday. The Goldman Sachs Group boosted their target price on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Robert W. Baird upped their price objective on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Royal Bank of Canada initiated coverage on Natera in a research report on Thursday, March 13th. They set an “outperform” rating and a $251.00 price objective on the stock. Finally, Piper Sandler upped their price objective on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $182.12.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.